Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Alemtuzumab

Brand: 
NICE TA: 312
Indication: Multiple sclerosis (relapsing-remitting) (NICE TA312)
Disease category: Malignant disease and immunosuppression
Commissioning responsibility: NHS England
PbR excluded: Yes

Background

Alemtuzumab is recommended as an option, within its marketing authorisation, for treating adults with active relapsing–remitting multiple sclerosis. The costing report states that the costing template uses current prices of comparator treatments without their respective discounts applied. This would make Alemtuzumab more expensive when discounts are applied to other options, but it is highly effective although has severe side effects.

Recommendation

LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

NICE TA312 - Alemtuzumab for treating relapsing‑remitting multiple sclerosis 

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red